Alessandro Rambaldi to Treatment Outcome
This is a "connection" page, showing publications Alessandro Rambaldi has written about Treatment Outcome.
Connection Strength
0.171
-
Long-term follow-up of recovered MPN patients with COVID-19. Blood Cancer J. 2021 06 16; 11(6):115.
Score: 0.034
-
Effect of novel agents on the risk of early death of newly diagnosed symptomatic multiple myeloma patients: A single Centre retrospective analysis. Am J Hematol. 2019 01; 94(1):E11-E13.
Score: 0.029
-
Phase II Study of Sequential Infusion of Donor Lymphocyte Infusion and Cytokine-Induced Killer Cells for Patients Relapsed after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2017 Dec; 23(12):2070-2078.
Score: 0.026
-
Detection of driver and subclonal mutations in myelofibrosis: clinical impact on pharmacologic and transplant based treatment strategies. Expert Rev Hematol. 2017 07; 10(7):627-636.
Score: 0.026
-
Randomized Trial Comparing R-CHOP Versus High-Dose Sequential Chemotherapy in High-Risk Patients With Diffuse Large B-Cell Lymphomas. J Clin Oncol. 2016 11 20; 34(33):4015-4022.
Score: 0.025
-
Haploidentical Stem Cell Transplantation With Posttransplant Cyclophosphamide Therapy vs Other Donor Transplantations in Adults With Hematologic Cancers: A Systematic Review and Meta-analysis. JAMA Oncol. 2019 12 01; 5(12):1739-1748.
Score: 0.008
-
Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients. Cancer Med. 2019 08; 8(9):4089-4092.
Score: 0.007
-
Cord blood-derived cytokine-induced killer cells combined with blinatumomab as a therapeutic strategy for CD19+ tumors. Cytotherapy. 2018 08; 20(8):1077-1088.
Score: 0.007
-
TP53 in adult acute lymphoblastic leukemia. Leuk Lymphoma. 2018 04; 59(4):778-789.
Score: 0.006
-
A short low-dose imatinib trial allows rapid identification of responsive patients in hypereosinophilic syndromes. Br J Haematol. 2009 Dec; 147(5):681-5.
Score: 0.004